Experimental evidence from several sources has identi®ed a link between mismatch repair de®ciency and cytotoxic drug resistance. Selection for cisplatin resistance in the human ovarian cancer cell line A2780, results in loss of expression of the mismatch repair protein hMLH1 in most (90%) of the resultant cisplatin-resistant cell lines. Here we demonstrate that the cisplatin sensitive parental cell line displays methylation of the promoter of only one hMLH1 allele, but that the resistant cell lines all exhibit hyper-methylation of the promoters of both hMLH1 alleles. Full methylation of all sites tested was found to be invariably associated with loss of hMLH1 expression, whereas a partial increase in methylation appears compatible with either loss or maintenance of expression. In addition treatment of two of the resistant cell lines with 5-azacytidine, a known inhibitor of methylation, results in re-expression of hMLH1. Clonogenic assays demonstrate that the 5-azacytidine treated cells show increased sensitivity to cisplatin. Furthermore, 12.5% (3/ 24) of ovarian tumours show hypermethylation of the hMLH1 promoter. Expression of hMLH1 is absent in the tumours that are hypermethylated, while all the unmethylated tumours still express the protein. This analysis suggests that methylation of the hMLH1 promoter may be a common mechanism for loss of hMLH1 expression, and possibly for cisplatin-resistance, in ovarian cancer.
Introduction
hMLH1 is the human homologue of the yeast mismatch repair gene MLH1 (Bronner et al., 1994) and has a central role in strand speci®c DNA mismatch repair (for review see Modrich, 1997) . The hMLH1 gene was originally identi®ed due to its involvement in the cancer susceptibility syndrome hereditary nonpolyposis colorectal carcinoma (HNPCC) (Bronner et al., 1994) , which results in a predisposition to colorectal carcinoma as well as a number of other tumours, including adenocarcinomas of the endometrium, stomach and ovary (Lynch, 1993) . Mutations in several of the mismatch repair genes have been found to be associated with HNPCC, with the vast majority of mutations being seen in either hMLH1 or hMSH2 (Liu et al., 1996) . Transgenic mice with genetic inactivation of mismatch repair genes have con®rmed the tumour susceptibility associated with defects in Mlh1, Msh2 and Pms2 (Prolla et al., 1997; Reitmair et al., 1996) , although no tumour susceptibility was observed in Pms1 knockouts (Prolla et al., 1997) . One of the striking features of the resulting mismatch repair-defective tumours is their greatly increased rates of mutation at microsatellite sequences, known as microsatellite instability (MIN+) (Aaltonen et al., 1993) . For many tumour types the MIN+ phenotype has also been detected in sporadically occurring disease (Eshleman and Markowitz, 1995) . For example in ovarian cancer about 15% of sporadic tumours exhibit the MIN+ phenotype (Hatta et al., 1997; Fujita et al., 1995; King et al., 1995) . This suggests that these tumours are also mismatch repair-defective, however, mutations of mismatch repair genes have only been observed at low frequency in MIN+ sporadic tumours (Liu et al., 1995) .
In addition to its role in the development of cancer, there is now strong evidence that defects in mismatch repair are responsible for the increased resistance observed in cancer cell lines to a variety of chemotherapeutic agents (Fink et al., 1998) . Furthermore embryonic stem cells from either Msh2 or Pms2 knockout mice were found to be intrinsically resistant to both cisplatin and carboplatin (Fink et al., 1997) . The importance of mismatch repair proteins in drug resistance has been further emphasized by chromosome transfer experiments. These showed that restoration of mismatch repair in hMLH1 de®cient cells by addition of Chromosome 3 (to which the hMLH1 gene maps (Bronner et al., 1994) ) resulted in increased sensitivity to both cisplatin and carboplatin .
The resistance of mismatch repair de®cient cells to cisplatin and carboplatin may be of particular importance in ovarian cancer. Cisplatin (or carboplatin), in combination with drugs such as paclitaxel, is the main chemotherapeutic treatment for ovarian cancer (Kaye, 1996) . The majority of tumours respond to chemotherapy, although about 20 ± 30% are intrinsically resistant to cisplatin, (Neijt, 1977) . However, even in tumours where initial response is good, relapse is common and the re-occurring tumour mass eventually becomes clinically resistant to further treatment (Kaye, 1996) . Several lines of evidence suggest a role for hMLH1 in the acquisition of resistance in ovarian tumours. An increased frequency of loss of expression of hMLH1 has been observed in post-chemotherapy tumours compared to pre-chemotherapy samples (Brown et al., 1997) . Also, in one ovarian carcinoma cell line, A2780, it has been shown that nine out of ten cisplatin resistant derivatives showed complete loss of hMLH1 protein expression (Brown et al., 1997) . Analysis of the resistant clones did not detect any apparent loss of the hMLH1 gene (Brown et al., 1997) and the mechanism by which expression is lost in the resistant cell lines is unknown. It has been reported in colorectal cancer that in some cell lines, as well as tumour samples, hMLH1 expression may be lost due to hypermethylation of the hMLH1 promoter, presumably resulting in suppression of transcription (Herman et al., 1998; Kane et al., 1997) . In this study we have examined the possible role of hypermethylation upon loss of expression of hMLH1 in cisplatin resistant ovarian carcinoma cell lines and also examined the methylation status and expression of hMLH1 in ovarian tumour samples.
Results
Methylation status of the hMLH1 promoter in cisplatin resistant derivatives of an ovarian cancer cell line Nine out of ten cisplatin-resistant cell lines, independently derived from A2780, show loss of expression of hMLH1 (Brown et al., 1997) . However, preliminary single strand conformation polymorphism (SSCP) and sequence analysis did not detect any mutations of hMLH1 (data not shown). Hypermethylation of eukaryotic promoters is nearly always associated with loss of expression of the associated gene (Zingg and Jones, 1997) . To determine if methylation of the hMLH1 promoter was responsible for the loss of expression seen in the resistant cell lines, we have assessed the ability of a methylation-insensitive restriction enzyme (MspI) and a methylation-sensitive restriction enzyme (HpaII), which have the same recognition sequence, to digest DNA sequences from the hMLH1 promoter, by Southern blot analysis ( Figure 1a) . As expected digestion with MspI resulted in only the 349 bp band in all the cell lines. For A2780, the parental cell line, digestion with HpaII resulted in the presence of both an 884 bp band, indicative of lack of HpaII digestion (and therefore methylation of the four HpaII sites) and also a 349 bp band which results from HpaII digestion at position 7567 (indicating the absence of methylation) (Figure 1b) . The intensities of the bands suggests that A2780 has roughly equal proportions of methylated and unmethylated DNA in the hMLH1 promoter. All ten resistant derivatives of A2780 showed increased methylation of the hMLH1 promoter compared to A2780 (examples shown in Figure 1b) . Eight of the ten resistant cell lines showed complete, or nearly complete, methylation of the four HpaII sites. However, HpaII digestion of two of the cell lines resulted in two bands of roughly equal intensity, the fully methylated 884 bp band and a novel 569 bp band. This new band is the result of partial methylation, with the two further upstream sites being methylated and at least one of the further downstream sites being unmethylated. One of these cell lines, A2780/MCP8, still expresses hMLH1, but the other, A2780/MCP4, is de®cient in hMLH1 expression (Brown et al., 1997) . Therefore, while the fully methylated pattern, in these cell lines, is invariably associated with loss of expression, partial methylation appears compatible with either maintenance or loss of hMLH1 expression. Southern blots were also performed with a probe covering the 3' end of the promoter region (7443 ± +16). The results con®rmed those presented above (data not shown).
Re-activation of hMLH1 expression
To attempt to determine if the methylation observed in the resistant cell lines was responsible for the loss of hMLH1 expression in the resistant cell lines, one of the cell lines, A2780/MCP3, was treated with 5-azacytidine, a known inhibitor of the human DNA methyltransferase enzyme. Cells treated with either 2 or 10 mm of the drug, for 24 h per passage, showed clear re-activation of hMLH1 expression, as judged by immunohistochemistry ( Figure 2a ; Table 1 ). A second cell line, A2780/MCP1, also showed re-activation of hMLH1 expression upon 5-azacytidine treatment. In this cell line higher levels of hMLH1 reactivation were achieved using an additional 4 day treatment with 10 mm 5-azacytidine immediately prior to immunohistochemical analysis (Table 1) . Furthermore, Southern blot analysis showed that treatment of A2780/MCP1 cells with 2 mm 5-azacytidine resulted in a reduction in hMLH1 promoter methylation, as evidenced by the reduction in the fully methylated 884 bp band and the appearance of the 529 bp partially methylated band ( Figure 1b ). This partially methylated band is compatible with hMLH1 expression, as shown for the A2780/MCP8 cell line (see above).
Cisplatin sensitivity of cell lines induced to re-express hMLH1
Clonogenic assays were performed to determine the eect of hMLH1 re-expression in the resistant line A2780/MCP3 on cisplatin sensitivity. A2780/MCP3 cells which had been treated with 0, 2 or 10 mm 5-azacytidine were exposed to 0, 10, 20 or 40 mm cisplatin for 1 h. The cells were then trypsinized, counted and a known cell number plated out to determine their clonogenic potential. As can be seen from Figure 2b , cells pre-treated with either 2 or 10 mm 5-azacytidine showed increased sensitivity to all concentrations of cisplatin compared to untreated A2780/MCP3 cells. However, the sensitivity of the treated cells does not correlate perfectly with hMLH1 re-expression, as cells treated with either concentration of 5-azacytidine restored sensitivity to parental levels, yet only partial restoration of MLH1 expression was detected. Treatment of the parental A2780 cell line with 2 mm 5-azacytidine had no signi®cant eect on cisplatin sensitivity (data not shown).
Methylation status of hMLH1 in ovarian tumours
About 15% of sporadically occurring ovarian tumours show microsatellite instability (Hatta et al., 1997; Fujita et al., 1995; King et al., 1995) , suggesting that there is a defect in mismatch repair in these tumours. To determine if methylation of the promoter region of hMLH1 could be a potential cause of mismatch repair defects in ovarian tumours, DNA was extracted from 24 ovarian tumour samples and used for Southern blot analysis. In most of the tumours digestion with HpaII gave only the 349 bp band, suggesting that there is no hMLH1 promoter methylation and drug resistance G Strathdee et al signi®cant methylation of the hMLH1 promoter (examples shown in Figure 1c ). However, in three of the tumours HpaII digestion resulted only in the 884 bp fragment, indicating that all four HpaII sites were methylated (examples shown in Figure 1c ). These results show that methylation of the hMLH1 promoter occurs in a signi®cant fraction of ovarian tumours.
To determine the eect of methylation of the promoter on expression of hMLH1, immunohistochemical analysis was performed on the ovarian tumour samples. All three of the methylation-positive tumours showed complete loss of hMLH1 expression (Figure 3a ± c) , whereas high levels of the hMLH1 protein were detected in all of the methylation-negative tumours (example shown in Figure 3d ). Staining for another mismatch repair protein, hMSH2, showed no dierence in expression between the methylationpositive and negative tumours (data not shown). 
Therefore hMLH1 was speci®cally lost in the tumours that exhibited hMLH1 promoter methylation.
Discussion
The results presented here demonstrate that in an ovarian tumour cell line, development of cisplatin resistance is associated with loss of hMLH1 expression due to hypermethylation of the hMLH1 promoter. Furthermore, a signi®cant proportion of ovarian tumours also showed hypermethylation of the hMLH1 promoter and concomitant loss of the hMLH1 protein. This suggests that hMLH1 promoter methylation could play a signi®cant role in determining the sensitivity of ovarian tumours to cisplatin, as well as other chemotherapeutic agents whose toxicities have been shown to be altered by mismatch repair defects in cancer cell lines (Fink et al., 1998) .
One question raised by the A2780 model for development of cisplatin resistance is why loss of hMLH1, and not other mismatch repair proteins, such as hMSH2, is seen. The answer appears to be that in the A2780 cell line, the promoter of one hMLH1 allele is inactivated by methylation and therefore loss of hMLH1 expression would only require loss of expression from the one unmethylated allele, whereas loss of any other mismatch repair protein would presumably require two separate mutagenic events. This could also potentially explain the speci®c loss of hMLH1 expression observed in other independent ovarian cell line models selected for cisplatin resistance .
A recent report (Herman et al., 1998) provided evidence that hMLH1 promoter methylation, and the resulting loss of expression, may be the underlying cause of the MIN+ phenotype in the vast majority sporadic colorectal tumours. We found 12.5% of ovarian tumours showed hMLH1 hypermethylation, and a corresponding loss of hMLH1 expression, only slightly below the frequency (15%) at which the MIN+ phenotype is estimated to occur in sporadic ovarian cancer (Hatta et al., 1997; Fujita et al., 1995; King et al., 1995) . Furthermore, we found that in all the tumours in which we did not detect promoter hypermethylation hMLH1 expression was high. Thus, in this tumour set, loss of hMLH1 expression was invariably associated with hypermethylation of the promoter region. In addition, the ®nding that hMLH1 is frequently inactivated by epigenetic rather than genetic events explains the low frequency with which structural mutations of mismatch repair genes The number in brackets after the cell line indicates the concentration of 5-azacytidine to which the line was exposed. (+10 mM) indicates an additional 4 day treatment with 10 mM 5-azacytidine. b MLH1 levels were assessed by immunohistochemistry. At least 50 cells were counted by selecting random areas of the slide and counting all the cells in the ®eld of view hMLH1 promoter methylation and drug resistance G Strathdee et al have been found in sporadic MIN+ tumours (Liu et al., 1995) . A more extensive study, including tumours with known MIN status, will be required to clearly determine if loss of hMLH1, due to hypermethylation, is the main cause of microsatellite instability in sporadic ovarian tumours. This paper demonstrates that 5-azacytidine treatment of cisplatin resistant derivatives of A2780 resulted in increased expression of the hMLH1 protein and a corresponding increase in cisplatin sensitivity. Surprisingly, however, there did not appear to be a direct correlation between the extent of re-expression of hMLH1 and the increase in cisplatin sensitivity. A possible explanation for this lack of correlation is that some or all of the increased sensitivity may be due to a synergistic interaction between 5-azacytidine and cisplatin. Such a synergy has been shown to exist between the closely related demethylating agent 2-deoxy-5-azacytidine and cisplatin (Frost et al., 1990) . However, we detected no increased cisplatin sensitivity in the parental A2780 cell line following 5-azacytidine treatment, suggesting that 5-azacytidine and cisplatin do not interact synergistically in this model. A second possible explanation is that the immunohistochemical assay used here may not be sensitive enough to detect low levels of hMLH1 expression and therefore the percentage of hMLH1 positive cells following 5-azacytidine treatment of the resistant cell lines may be higher than the immunohistochemical results suggest.
For the majority of the ovarian tumour samples (15/ 24) examined in this report we were able to obtain the patient's clinical records. Unfortunately it was not possible to draw de®nite conclusions about the prognostic signi®cance of loss of hMLH1 expression, due to the small sample size. Interestingly though, this analysis did show an apparent increase in hMLH1 promoter methylation and loss of expression in postplatinum treated tumours (50%; 2/4) compared with primary tumour samples (9%; 1/11). This agrees with a previous study which also showed an increase in loss of hMLH1 expression in post-platinum treated samples (Brown et al., 1997) . A larger study is currently underway to allow the role of hMLH1 expression in the response to treatment of ovarian tumours to be more clearly de®ned.
The A2780 cell population from which the resistant cell lines were derived, may contain a small subpopulation of cells with methylation of both alleles of hMLH1. This mismatch repair de®cient subpopulation would then be selected for by exposure to cisplatin. Interestingly, however, it has been shown that exposure of human cancer cells to cisplatin in vitro induces genome wide hypermethylation (Nyce, 1989) . Although this eect was observed in response to a number of cytotoxic drugs the hypermethylation induced by cisplatin was considerably more pronounced than that induced by any of the other drugs. The hypermethylation in response to cisplatin was also seen at much lower drug concentrations, including the relatively low concentrations to which the resistant cell lines, used in this study, were exposed, and indeed at levels that are physiologically relevant during treatment of cancer patients with cisplatin. Therefore, in the resistant cell lines, methylation of the second hMLH1 allele may have occurred as a direct consequence of exposure of the cells to cisplatin. The results presented here and those referred to above for colorectal cancers suggest that the hMLH1 promoter appears particularly susceptible to hypermethylation. Therefore, cisplatin based treatment of ovarian cancer may tend to induce hypermethylation of the hMLH1 promoter and thus increased resistance to the drug.
Materials and methods

Cell lines and clonogenic assays
All cell lines were grown as monolayer cultures in RPMI 1640 medium (Life Technologies Inc.) with 10% foetal calf serum in 95% air/5% CO 2 at 378C and routinely checked for mycoplasma. For clonogenic drug sensitivity assays, cells were grown to about 15% con¯uency and then exposed to cisplatin (dissolved in DMSO) for 1 h at 378C. The cells were then trypsinized, counted using an automated cell counter (Scharfe System) and plated out on 10-cm dishes at 2610 3 ± 7.5610 5 cells/dish. After incubation of the plates for 12 ± 14 days, colonies were stained with giemsa (BDH Laboratory Supplies) and counted.
Tumour samples
Tumour samples were obtained from either the Western In®rmary or Stobhill General Hospitals, Glasgow and included samples taken before and after chemotherapeutic treatment. Tumour samples were stored frozen at 7708C. Patient records were obtained where possible.
Southern blotting
Genomic DNA was isolated from cell lines using the Nucleon I kit (Scotlab), as per manufacturers protocol. Genomic DNA was isolated from frozen ovarian tumour Figure 3 Dependence of hMLH1 expression in tumours on methylation status of the hMLH1 promoter. Tumour samples that exhibited hypermethylation of the hMLH1 promoter region (a ± c) or no methylation (d), were analysed for hMLH1 expression using immunohistochemistry. hMLH1 expressing cells are identi®ed by the brown staining in the nucleus. The nuclei of non-expressing cells are blue due to haematoxylin counterstaining hMLH1 promoter methylation and drug resistance G Strathdee et al samples by ®rst crushing the frozen sample with a mortar and pestle. Samples were then powdered using a mikrodismembrator II (B.Braun) and added to 10 ml lysis buer containing 0.3 M sodium acetate pH 8.0, 0.5% SDS, 5 mM EDTA and 50 ug/ml proteinase K and left shaking at 378C overnight. The following day samples were extracted with phenol and chloroform:isoamly alcohol (24 : 1) and then precipitated in 1/10 volume of 8 M sodium acetate and two volumes of 100% ethanol.
To allow the methylation status of the hMLH1 promoter to be determined, 30 mg of genomic DNA was ®rst digested with EcoRV and XbaI (Life Technologies Inc.) at 378C for 6 h to release an 884 bp fragment of the hMLH1 promoter (from 7915 to 731 (see Figure 1) ). The digested DNA was then split evenly into three tubes and further digested with either HpaII, MspI (Life Technologies Inc.) or no enzyme for 6 h at 378C. The DNA was run on a 1% agarose gel and then blotted onto HybondN membrane (Amersham Life Science) as per standard protocols.
The probe was made by PCR ampli®cation of a 421 bp region of the hMLH1 promoter (from 7910 to 7490 (see Figure 1) ) using 25 ml PCR reactions that contained 10 mM Tris-HCL (pH 8.3), 50 mM KCl, 1.5 mM MgCl, 10 mM dNTPs, 50 ng of genomic DNA, 0.75 units of Taq DNA polymerase (Boehringer Mannheim) and 75 ng of each primer (MLH-SB-F 5'-GGAGATAAGTCAACGCCTTG-3' and MLH-SB-R 5'-GAAGCAAGATGGAAGTCGAC-3'). PCR was performed with one cycle of 958C for 5 min, 35 cycles of 948C for 30 s, 558C for 30 s and 728C for 45 s, followed by one cycle of 728C for 5 min. The PCR products were run on a 1% agarose gel and the 421 bp fragment was cut out and puri®ed using a GenElute agarose spin Column (Sigma).
Labelling of the probe was performed using the Prime-It II (Stratagene) random labelling kit, as per the manufacturers protocol. Hybridization was carried out in buer containing 50 mM PIPES, 50 mM NaH 2 PO 4 .2H 2 O, 50 mM Na 2 HPO 4 100 mM NaCl, 1 mM EDTA and 5% SDS in a hybridization oven at 658C overnight. The following day the blots were washed once for 30 min in 26SSC/0.2% SDS and once for 30 min in 0.56SSC/0.2% SDS. Autoradiography was performed using Kodak Xomat ®lm, with exposures of 1 ± 14 days.
5-azacytidine treatment
5-azacytidine was dissolved in 50% acetic acid at a concentration of 8.2 mM. Cells were grown in 75-cm 2 tissue culture¯asks (Corning) and passaged once a week. Cells were exposed to one 24 h treatment with 5-azacytidine per passage by adding 5-azacytidine to a concentration of 2 or 10 mm to the tissue culture media the day preceding passaging of the cells (control cells were treated with a similar volume of 50% acetic acid without 5-azacytidine). After 24 h the culture media was changed and replaced with fresh media not containing 5-azacytidine. For clonogenic assays, the ®nal exposure to 5-azacytidine was 7 days prior to cisplatin treatment.
Immunohistochemistry
For cells in culture, the cells were passed into 8-well chamber slides (Nalge Nunc International) at 4610 4 cells/ well and grown for 2 days. They were then washed with PBS and allowed to air dry for 30 min. The slides were then either frozen at 7208C for later use or ®xed immediately in 7208C methanol. After 20 min in the ®x the slides were removed and allowed to air dry for 30 min. The slides were then blocked for 20 min at room temperature in normal horse serum (diluted 1 : 10 in PBS/ 0.1% BSA). The slides were then incubated with monoclonal anti-hMLH1 mouse IgG (Cambridge Bioscience) (diluted to 2.5 mg/ml in PBS/0.1% BSA) for 2 hours at room temperature. Next the slides were washed twice in PBS/0.1% Tween for 10 min and then incubated with FITC conjugated anti-mouse IgG goat antibody (Sigma) (diluted to 90 mg/ml in PBS/0.1% BSA) for 30 min at room temperature. After a further two 10 min washes in PBS/0.1% Tween, the slides were mounted with VectaShield (Vector Laboratories) and examined with a Nikon epi¯uorescence microscope. Images were analysed using the CoMOS image analysis package (BioRad).
For paran-embedded tumour samples immunohistochemistry was carried out essentially as described before (Thibodeau et al., 1996) , except the primary antibody was used at a concentration of 5 mg/ml.
